Literature DB >> 23254310

The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.

Tomasz P Lehmann1, Tomasz Wrzesiński, Paweł P Jagodziński.   

Abstract

Mitotane, also known as o,p'‑DDD or (RS)‑1‑chl-oro‑2‑[2,2‑dichloro‑1‑(4‑chlorophenyl)‑ethyl]‑benzene, is an adrenal cortex-specific cytotoxic drug used in the therapy of adrenocortical carcinoma (ACC). The drug also inhibits steroidogenesis, however, the mechanisms of its anticancer and antisteroidogenic effects remain unknown. At present, data on the impact of mitotane on cell viability and the regulation of genes encoding proteins associated with steroids synthesis in the adrenal cortex, including cortisol and dehydroepiandrosterone sulfate (DHEAS), are limited and contradictory. In the present study, the effect of 24‑h mitotane treatment on viability of the ACC cell line, NCI‑H295R, was analyzed, identifying a decrease in cell viability and an increase in caspase‑3 and ‑7 activities. Mitotane treatment also led to decreased cortisol and DHEAS concentration in the culture media. Concomitantly, mitotane resulted in decreased mRNA levels of two cytochromes P450 (CYP11A1 and CYP17A1), mRNAs encoding proteins involved in the synthesis of cortisol and DHEAS. Mitotane did not affect mRNA levels of cyclin dependent kinase inhibitor 1A (encoding p21) and MYC (encoding cMyc). cMyc and p21 are key transcription factors associated with cell cycle regulation. However, mitotane inhibited expression of transforming growth factor β1 gene, encoding a potent inhibitor of cell proliferation and steroidogenesis. PRKAR1A, a protein kinase A regulatory subunit, is involved in the activation of steroidogenesis. PRKAR1A mRNA levels were reduced following 24‑h treatment with mitotane. Results indicate that mitotane markedly inhibited expression of genes involved in steroidogenesis, secretion of cortisol and DHEAS. Reduced expression of TGFB1 cannot account fully for the effect of mitotane on CYP11A1 and CYP17A1. We hypothesized that reduced viability of NCI‑H295R cells in the presence of mitotane may be a result of apoptosis triggered by increased caspase‑3 and ‑7 activities. Since p21 and cMyc mRNA levels were stable in the presence of mitotane, the mechanism by which caspase‑3 and ‑7 are induced remains unknown.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23254310     DOI: 10.3892/mmr.2012.1244

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  16 in total

1.  The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.

Authors:  Ségolène Hescot; Angelo Paci; Atmane Seck; Abdelhamid Slama; Say Viengchareun; Séverine Trabado; Sylvie Brailly-Tabard; Abir Al Ghuzlan; Jacques Young; Eric Baudin; Marc Lombès
Journal:  Horm Cancer       Date:  2014-07-16       Impact factor: 3.869

2.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

3.  Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma.

Authors:  Timothy D Murtha; Taylor C Brown; Jill C Rubinstein; Felix Haglund; C Christofer Juhlin; Catharina Larsson; Reju Korah; Tobias Carling
Journal:  Surgery       Date:  2017-01-07       Impact factor: 3.982

4.  Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.

Authors:  Dirk Theile; Walter Emil Haefeli; Johanna Weiss
Journal:  Endocrine       Date:  2014-12-27       Impact factor: 3.633

5.  EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report.

Authors:  Zhipeng Zhang; Ningning Liu; Qi Li
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

6.  Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.

Authors:  You Joung Heo; Jae Ho Yoo; Yun Soo Choe; Sang Hee Park; Seung Bok Lee; Hyun A Kim; Jung Yoon Choi; Young Ah Lee; Byung Chan Lim; Hee Won Chueh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2021-10-18

7.  GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.

Authors:  Adele Chimento; Rosa Sirianni; Ivan Casaburi; Fabiana Zolea; Pietro Rizza; Paola Avena; Rocco Malivindi; Arianna De Luca; Carmela Campana; Emilia Martire; Francesco Domanico; Francesco Fallo; Giulia Carpinelli; Lidia Cerquetti; Donatella Amendola; Antonio Stigliano; Vincenzo Pezzi
Journal:  Oncotarget       Date:  2015-08-07

8.  CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.

Authors:  Antonina Germano; Laura Saba; Silvia De Francia; Ida Rapa; Paola Perotti; Alfredo Berruti; Marco Volante; Massimo Terzolo
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

9.  The effects of mitotane and 1α,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells.

Authors:  B Rubin; C Pilon; R Pezzani; A Rebellato; F Fallo
Journal:  J Endocrinol Invest       Date:  2019-10-05       Impact factor: 4.256

10.  Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.

Authors:  Nada El Ghorayeb; Geneviève Rondeau; Mathieu Latour; Christian Cohade; Harold Olney; André Lacroix; Paul Perrotte; Alexis Sabourin; Tania L Mazzuco; Isabelle Bourdeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.